tradingkey.logo

Bausch Health falls after RBC Capital Markets lowers PT

ReutersApr 7, 2025 3:36 PM

U.S.-listed shares of eye care firm Bausch Health BHC.TO down 4.2% at $5.06

Brokerage RBC Capital Markets cuts PT to $8.5 from $9 ahead of Q1 results, maintains "sector perform" rating

The new price target represents a 59.5% upside to the stock's last close

Company is set to share Q1 results on April 30 - brokerage

RBC estimates Q1 revenue of $2.24 billion on "broader macroeconomic uncertainty currently"

"If a sale of BLCO were to take place, we anticipate it would most likely happen in the 2026-2027 time frame" - RBC

Bausch + Lomb BLCO.TO said in December 2024 it is exploring a potential sale among other options, in a move that would help Canadian parent Bausch Health BHC.TO exit the eye-care company

Brokerage says BLCO's dry-eye treatment, Miebo, will turn profitable in 2026

Up to Friday's close, stock had fallen 35.4% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI